Azelastine and flezelastine as reversing agents of multidrug resistance: Pharmacological and molecular studies
- 17 July 1995
- journal article
- research article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 50 (2) , 169-175
- https://doi.org/10.1016/0006-2952(95)00130-r
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Enhanced cytotoxicity of doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres against multidrug-resistant tumour cells in cultureEuropean Journal Of Cancer, 1994
- BIOCHEMISTRY OF MULTIDRUG RESISTANCE MEDIATED BY THE MULTIDRUG TRANSPORTERAnnual Review of Biochemistry, 1993
- Reversal of multidrug resistance by a new lipophilic cationic molecule, S9788. Comparison with 11 other MDR-modulating agents in a model of doxorubicin-resistant rat glioblastoma cellsEuropean Journal Of Cancer, 1993
- P-glycoprotein and resistance to anticancer drugsCancer, 1992
- Photoaffinity Labeling of P-Glycoprotein in Multidrug-Resistant CellsCancer Investigation, 1992
- Potential usefulness of quinine to circumvent the anthracycline resistance in clinical practiceBritish Journal of Cancer, 1990
- Multidrug Resistance and Chemosensitization: Therapeutic Implications for Cancer ChemotherapyPublished by Elsevier ,1990
- Circumvention of Adriamycin-Resistance of Leukemia Cells by the Anti-Allergic Drug AzelastineJournal of Clinical Biochemistry and Nutrition, 1989
- Reversal of drug‐resistance in multiple myeloma with verapamilBritish Journal of Haematology, 1988
- Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro.Journal of Clinical Investigation, 1986